Prosecution Insights
Last updated: May 29, 2026
Application No. 19/215,242

COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL

Final Rejection §103
Filed
May 21, 2025
Priority
Oct 25, 2022 — provisional 63/419,155 +4 more
Examiner
HENLEY III, RAYMOND J
Art Unit
1629
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
VERADERMICS INCORPORATED
OA Round
2 (Final)
84%
Grant Probability
Favorable
3-4
OA Rounds
10m
Est. Remaining
86%
With Interview

Examiner Intelligence

Grants 84% — above average
84%
Career Allowance Rate
1043 granted / 1249 resolved
+23.5% vs TC avg
Minimal +2% lift
Without
With
+2.1%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 10m
Avg Prosecution
28 currently pending
Career history
1282
Total Applications
across all art units

Statute-Specific Performance

§101
2.0%
-38.0% vs TC avg
§103
24.1%
-15.9% vs TC avg
§102
5.5%
-34.5% vs TC avg
§112
25.3%
-14.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1249 resolved cases

Office Action

§103
CLAIMS 1-21 ARE PRESENTED FOR EXAMINATION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicant’s Amendment/remarks filed February 12, 2026 have been received and entered into the application. In light thereof, the rejection of the claims under 35 USC 103, as set forth in the previous Office action, has been overcome and is hereby withdrawn. Double Patenting Applicant has deferred responding to the rejections below. Both double patenting rejections are deemed to remain proper for the reasons set forth in the previous Office action, which reasons are here incorporated by reference. Provisional Claims 1-21 remain provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-20, (unless otherwise specified), of copending Application Nos. (reference applications).19/094,716; 19/253,703; 19/253,708; 19/255,878; 19/230,047, (claims 1-21); 19/230,054, (claims 1-21); 19/258,817; 19/260,035; 19/267,447; 19/267,464; 19/308,124; 19/315,454, (claims 1-19); 19/328,077, (claims 1-19); or 19/329,494, (claims 1-19). This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Non-Provisional Claims 1-21 remain rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-28 of U.S. Patent No. 12,268,688, (cited by Applicant) or (b) claims 1-20 of U.S. Patent No. 12,491,184, (cited by the Examiner). Accordingly, the claims are deemed properly rejected and none are currently in condition for allowance. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to RAYMOND J HENLEY III whose telephone number is (571)272-0575. The examiner can normally be reached M-F 6-2:30pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey S Lundgren can be reached on 571-272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /RAYMOND J HENLEY III/Primary Examiner, Art Unit 1629 March 26, 2026
Read full office action

Prosecution Timeline

May 21, 2025
Application Filed
Jan 26, 2026
Non-Final Rejection mailed — §103
Feb 09, 2026
Interview Requested
Feb 12, 2026
Response Filed
Feb 12, 2026
Interview Requested
Feb 25, 2026
Examiner Interview Summary
Feb 25, 2026
Applicant Interview (Telephonic)
Mar 30, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12629370
TREATMENT OF PROSTATE CANCER
10m to grant Granted May 19, 2026
Patent 12616752
PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM
11m to grant Granted May 05, 2026
Patent 12611416
METHODS OF TREATING ISCHEMIC STROKE AT RISK FOR CEREBRAL OR CEREBELLAR EDEMA
11m to grant Granted Apr 28, 2026
Patent 12605332
TRANSDERMAL DELIVERY FORMULATIONS
3y 5m to grant Granted Apr 21, 2026
Patent 12599604
APPLICATION OF JAK INHIBITOR IN KIDNEY DISEASE
2y 10m to grant Granted Apr 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
84%
Grant Probability
86%
With Interview (+2.1%)
1y 10m (~10m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1249 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month